Fortrea reported third-quarter revenue of $691 million, down 1.4% from the prior-year period, while adjusted EBITDA improved by 14% to $58 million. Management raised its 2026 revenue and adjusted EBITDA guidance by 85 basis points and 71 basis points, respectively, at the midpoint.
Fortrea is poised to benefit from steadily increasing levels of outsourced clinical trials and complex novel therapeutics, such as biologics and gene therapies.
Fortrea's margin improvement depends on disciplined cost actions while winning new business, and any operational challenges could delay its recovery.
|
Metric
|
FTRE
|
ICLR
|
IQV
|
|---|---|---|---|
Price/Earnings (Normalized) | 159.26 | 28.64 | 27.04 |
Price/Book Value | 3.86 | 1.73 | 6.62 |
Price/Sales | 0.75 | 1.97 | 2.61 |
Price/Cash Flow | 35.62 | 17.61 | 16.85 |
|
Metric
|
FTRE
|
ICLR
|
IQV
|
|---|---|---|---|
Quick Ratio | 0.88 | 1.27 | 0.74 |
Current Ratio | 0.97 | 1.32 | 0.83 |
Interest Coverage | 0.36 | 3.49 | 2.93 |
|
Metric
|
FTRE
|
ICLR
|
IQV
|
|---|---|---|---|
Return on Assets (Normalized) | −0.67% | 3.47% | 7.28% |
Return on Equity (Normalized) | −3.36% | 6.12% | 34.12% |
Return on Invested Capital (Normalized) | 2.54% | 5.69% | 12.43% |
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|Vt&R?g! | LOCK|t%HJ | $142B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|<>@<>M | LOCK|^tHj | $96B | |||
| Moderna Inc
MRNA
| LOCK|&ZB#RJ | LOCK|nt^ | $89B | |||
| argenx SE ADR
ARGX
| LOCK|&<>$^$ | LOCK|z>q | $57B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|LK@k>Z | LOCK|$> | $43B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|sv#>sY?F | LOCK|#p%K | $30B | |||
| Incyte Corp
INCY
| LOCK|&T<Bh@ | LOCK|^p | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|THRD@<% | LOCK|#p | $22B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|b>X^^FB | LOCK|bH&^ | $22B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|Ql#D%>B | LOCK|&$ | $15B |
United States